Summary
Boston Scientific Corporation (BSX) has announced a significant strategic move with the signing of a definitive merger agreement to acquire Sadra Medical, Inc. This acquisition is set to enhance BSX's presence in the cardiovascular market by adding Sadra's innovative, fully repositionable device for percutaneous aortic valve replacement. This technology addresses a critical need for patients suffering from severe aortic stenosis, offering a potentially less invasive treatment option compared to traditional open-heart surgery.
Key Highlights
- 1Boston Scientific (BSX) to acquire Sadra Medical, Inc.
- 2Acquisition targets a development-stage company with a novel medical device.
- 3Sadra Medical is developing a fully repositionable device for percutaneous aortic valve replacement.
- 4The technology aims to treat patients with severe aortic stenosis.
- 5Transaction is expected to close in late 2010 or early 2011.
- 6This acquisition strengthens BSX's cardiovascular portfolio.
Frequently Asked Questions
The primary purpose is to expand Boston Scientific's cardiovascular product line with Sadra Medical's innovative aortic valve replacement technology. This move is expected to bolster their competitive position in the treatment of severe aortic stenosis.
Sadra Medical is developing the first fully repositionable device designed for percutaneous aortic valve replacement, a less invasive approach to treating severe aortic stenosis.
The closing of the transaction is anticipated to occur in the fourth quarter of 2010 or the first quarter of 2011, subject to customary closing conditions.
The filing does not disclose specific financial terms or the purchase price of the acquisition. Further details on the financial implications would likely be released at closing or in subsequent filings.